Previous close | 20.60 |
Open | 20.60 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 760.00 |
Expiry date | 2024-11-15 |
Day's range | 20.60 - 20.60 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Insightful Analysis of Regeneron's Financials and Strategic Positioning
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.